IP Library Granted Patent US 10,457,916
Granted Patent B2
US 10,457,916 · App. 15/312,273 · Granted Oct 29, 2019

Method for inducing differentiation of insulin-producing cells

Inventors: Shoen Kume (Tokyo, JP); Nobuaki Shiraki (Tokyo, JP)
Assignee: Tokyo Institute of Technology
C12N5/0676A61K35/12C12N5/0678G01N33/507G01N33/5073G01N33/74C12N15/09C12N2500/92C12N2500/98C12N2501/01C12N2501/119C12N2501/15C12N2501/155C12N2501/16C12N2501/385C12N2501/41C12N2501/415C12N2501/727C12N2501/73C12N2506/45C12N2533/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,457,916
App. No.
15/312,273
Granted
Oct 29, 2019
Kind
B2
Abstract

It is an object of the present invention to provide a method for efficiently directing differentiation into insulin-producing cells in a xeno-free culture system. According to the present invention, there is provided a method for directed differentiation into insulin-producing cells, comprising culturing stem cells in the following steps (1) to (5): (1) a step of culturing stem cells in a medium comprising an activator of activin receptor-like kinase-4/-7 and a GSK3 inhibitor and then culturing in a medium comprising an activator of activin receptor-like kinase-4/-7; (2) a step of culturing the cells obtained in step (1) in a medium comprising a hedgehog signaling inhibitor and an FGF; (3) a step of culturing the cells obtained in step (2) in a medium comprising a retinoic acid receptor agonist, a hedgehog signaling inhibitor and a BMP signaling inhibitor; (4) a step of culturing the cells obtained in step (3) in a medium comprising a TGF-β type I activin receptor-like kinase-4/-5/-7 inhibitor and a BMP signaling inhibitor; and (5) a step of culturing the cells obtained in step (4) in a medium comprising a phosphodiesterase inhibitor.

Claims (38)

1. A method for directed differentiation into insulin-producing cells, comprising culturing endodermal cells in the following steps (a) to (d):

(a) culturing the endodermal cells in a medium comprising a hedgehog signaling inhibitor and an FGF;

(b) culturing the cells obtained in step (a) in a medium comprising a retinoic acid receptor agonist, a hedgehog signaling inhibitor and noggin;

(c) culturing the cells obtained in step (b) in a medium comprising a TGF-β type I activin receptor-like kinase-4/-5/-7 inhibitor and noggin; and

(d) culturing the cells obtained in step (c) in a medium comprising GLP-1 receptor agonist and nicotinamide to produce insulin-producing cells,

wherein the concentration of the noggin in steps (b) and (c) is at least 200 ng/ml or more.

2. The method of claim 1 , wherein the concentration of the noggin in steps (b) and (c) is 200-500 ng/ml.

3. The method of claim 1 , wherein step (c) further comprises a protein kinase C activator.

4. The method of claim 1 , wherein the retinoic acid receptor agonist in step (b) is retinoic acid and the hedgehog signaling inhibitor in steps (a) and (b) is KAAD-cyclopamine.

5. The method of claim 3 , wherein the protein kinase C activator is indolactam V.

6. The method of claim 1 , which is characterized by conducting all of the steps (a) to (d) in a xeno-free culture system.

7. The method of claim 1 , wherein the endodermal cells are differentiated from pluripotent stem cells or embryonic stem cells.

8. The method of claim 1 , further comprising, before step (a), (1-1) culturing human or mouse pluripotent stem cells in a medium comprising an activator of activing receptor-like kinase-4/-7 and a GSK3 inhibitor and then (1-2) culturing in a medium comprising an activator of activing receptor-like kinase-4/-7 to effect differentiation into endodermal cells.

9. The method of claim 8 , wherein the medium in step (1-2) does not comprise a GSK3 inhibitor.

10. The method of claim 8 , all of the steps (1-1) to (d) are in a xeno-free culture system.

11. The method of claim 1 , wherein the hedgehog signaling inhibitor is SANT-1.

12. The method of claim 1 , wherein FGF is FGF10.

13. The method of claim 1 , wherein the BMP signaling inhibitor is LDN193189.

14. The method of claim 1 , wherein the retinoic acid receptor agonist is retinoic acid.

15. The method of claim 1 , wherein the TGF-β type I activin receptor-like kinase-4/-5/-7 inhibitor is Alk5 inhibitor.

16. The method of claim 1 , wherein the GLP-1 receptor agonist is exendin-4.

17. The method of claim 1 , further comprising isolating the cells from step (d).

18. The method of claim 1 , wherein the medium of step (d) excludes a growth factor.

19. A method for directed differentiation into mature insulin-producing cells, comprising culturing endodermal cells in the following steps (a) to (d):

(a) culturing the endodermal cells in a medium comprising SANT-1 and FGF10;

(b) culturing the cells obtained in step (a) in a medium comprising retinoic acid, SANT-1 and noggin;

(c) culturing the cells obtained in step (b) in a medium comprising Alk5 inhibitor, noggin, and indolactam V; and

(d) culturing the cells obtained in step (c) in a medium comprising nicotinamide and exendin-4 to produce insulin-producing cells,

wherein the concentration of the noggin in steps (b) and (c) is at least 200 ng/ml or more.

20. A method for directed differentiation into mature insulin-producing cells, the method consisting of:

(a) culturing human or mouse pluripotent stem cells in a medium comprising an activator of activing receptor-like kinase-4/-7 and a GSK3 inhibitor;

(b) culturing the cells of step (a) in a medium comprising an activator of activing receptor-like kinase-4/-7 to effect differentiation into endodermal cells;

(c) culturing the endodermal cells of step (b) in a medium comprising a hedgehog signaling inhibitor and an FGF;

(d) culturing the cells obtained in step (c) in a medium comprising a retinoic acid receptor agonist, a hedgehog signaling inhibitor and a BMP signaling inhibitor;

(e) culturing the cells obtained in step (d) in a medium comprising a TGF-β type I activin receptor-like kinase-4/-5/-7 inhibitor and a BMP signaling inhibitor; and

(f) culturing the cells obtained in step (e) in a medium comprising GLP-1 receptor agonist and nicotinamide to produce insulin-producing cells.

21. The method of claim 19 , wherein the concentration of noggin in steps (b) and (c) is 200-500 ng/ml.

22. The method of claim 20 , wherein the endodermal cells are differentiated from pluripotent stem cells or embryonic stem cells.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2016
From: KUME, SHOEN; SHIRAKI, NOBUAKI
To: TOKYO INSTITUTE OF TECHNOLOGY
Reel/Frame 040496/0656 →
Priority Claims (1)
JP 2014-104019 · May 20, 2014 · national
Continuity (1)
Related Publication 20170081639A1 · Mar 23, 2017
Cited By (3)
US 12,215,355 US 12,421,499 US 12,637,661